These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
288 related articles for article (PubMed ID: 19733036)
1. Efficacy of a new formulation of amphotericin B in murine disseminated infections by Candida glabrata or Candida tropicalis. Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J Int J Antimicrob Agents; 2009 Dec; 34(6):566-9. PubMed ID: 19733036 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata. Mariné M; Espada R; Torrado J; Pastor FJ; Guarro J J Antimicrob Chemother; 2008 Apr; 61(4):880-3. PubMed ID: 18256113 [TBL] [Abstract][Full Text] [Related]
3. Combined antifungal therapy in a murine infection by Candida glabrata. Mariné M; Serena C; Pastor FJ; Guarro J J Antimicrob Chemother; 2006 Dec; 58(6):1295-8. PubMed ID: 17012301 [TBL] [Abstract][Full Text] [Related]
4. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. Warn PA; Sharp A; Morrissey G; Denning DW J Antimicrob Chemother; 2005 Sep; 56(3):590-3. PubMed ID: 16046462 [TBL] [Abstract][Full Text] [Related]
5. In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation. Espada R; Valdespina S; Dea MA; Molero G; Ballesteros MP; Bolás F; Torrado JJ J Antimicrob Chemother; 2008 May; 61(5):1125-31. PubMed ID: 18285313 [TBL] [Abstract][Full Text] [Related]
6. Toxicity, stability and pharmacokinetics of amphotericin B in immunomodulator tuftsin-bearing liposomes in a murine model. Khan MA; Owais M J Antimicrob Chemother; 2006 Jul; 58(1):125-32. PubMed ID: 16709592 [TBL] [Abstract][Full Text] [Related]
7. Activities of flucytosine, fluconazole, amphotericin B, and micafungin in a murine model of disseminated infection by Candida glabrata. Mariné M; Serena C; Fernández-Torres B; Pastor FJ; Guarro J Antimicrob Agents Chemother; 2005 Nov; 49(11):4757-9. PubMed ID: 16251323 [TBL] [Abstract][Full Text] [Related]
8. Efficacy of alternative dosing regimens of poly-aggregated amphotericin B. Espada R; Valdespina S; Molero G; Dea MA; Ballesteros MP; Torrado JJ Int J Antimicrob Agents; 2008 Jul; 32(1):55-61. PubMed ID: 18534826 [TBL] [Abstract][Full Text] [Related]
9. Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin. Olson JA; Adler-Moore JP; Smith PJ; Proffitt RT Antimicrob Agents Chemother; 2005 Dec; 49(12):4895-902. PubMed ID: 16304150 [TBL] [Abstract][Full Text] [Related]
10. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. Smith PJ; Olson JA; Constable D; Schwartz J; Proffitt RT; Adler-Moore JP J Antimicrob Chemother; 2007 May; 59(5):941-51. PubMed ID: 17400589 [TBL] [Abstract][Full Text] [Related]
11. Tolerance to amphotericin B in clinical isolates of Candida tropicalis. Barchiesi F; Maracci M; Baldassarri I; Spreghini E; Giannini D; Scalise G Diagn Microbiol Infect Dis; 2004 Nov; 50(3):179-85. PubMed ID: 15541603 [TBL] [Abstract][Full Text] [Related]
12. The comparative efficacy of cilofungin, fluconazole and amphotericin B in disseminated Candida tropicalis infection in neutropenic mice. Fong IW; Bannatyne RM; Cheng PC Clin Invest Med; 1992 Oct; 15(5):434-9. PubMed ID: 1458716 [TBL] [Abstract][Full Text] [Related]
13. Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans. Brime B; Molero G; Frutos P; Frutos G Eur J Pharm Sci; 2004 Aug; 22(5):451-8. PubMed ID: 15265515 [TBL] [Abstract][Full Text] [Related]
14. Efficacy of liposomal amphotericin B against four species of Candida biofilms in an experimental mouse model of intravascular catheter infection. Fujimoto K; Takemoto K J Infect Chemother; 2018 Dec; 24(12):958-964. PubMed ID: 30209024 [TBL] [Abstract][Full Text] [Related]
15. High purity amphotericin B. Cleary JD; Chapman SW; Swiatlo E; Kramer R J Antimicrob Chemother; 2007 Dec; 60(6):1331-40. PubMed ID: 17921178 [TBL] [Abstract][Full Text] [Related]
16. Effects of amphotericin B incorporated into liposomes and in lipid suspensions in the treatment of murine candidiasis. Kretschmar M; Nichterlein T; Hannak D; Hof H Arzneimittelforschung; 1996 Jul; 46(7):711-5. PubMed ID: 8842344 [TBL] [Abstract][Full Text] [Related]
17. Influence of fungicidal activity against Candida tropicalis on the efficacy of micafungin and liposomal amphotericin B in a neutropenic murine lethal infection model. Takemoto K; Nakayama T; Kanazawa K; Ueda Y Pharmacology; 2012; 90(3-4):133-45. PubMed ID: 22847175 [TBL] [Abstract][Full Text] [Related]
18. Comparative efficacy and distribution of lipid formulations of amphotericin B in experimental Candida albicans infection of the central nervous system. Groll AH; Giri N; Petraitis V; Petraitiene R; Candelario M; Bacher JS; Piscitelli SC; Walsh TJ J Infect Dis; 2000 Jul; 182(1):274-82. PubMed ID: 10882607 [TBL] [Abstract][Full Text] [Related]
20. What is the current and future status of conventional amphotericin B? Kleinberg M Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]